Linked Life Data

16271384

Source:http://linkedlifedata.com/resource/pubmed/id/16271384

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-2-28
pubmed:abstractText
To evaluate the efficacy and tolerability of imatinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and primary peritoneal cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0090-8258
pubmed:author
pubmed:issnType
Print
pubmed:volume
101
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
126-31
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
pubmed:affiliation
Department of Gynecologic Oncology, Pathology, and Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. rcoleman@mdanderson.org
pubmed:publicationType
Journal Article, Clinical Trial, Phase II